Clinical trial
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With…
NCT00477672 · ACADIA Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT00477672 |
|---|---|
| Title | A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis |
| Official title | A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease |
| Lead sponsor | ACADIA Pharmaceuticals Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease Psychosis |
| Intervention type | Drug |
| Interventions | Pimavanserin tartrate (ACP-103), Placebo |
| Enrollment | 298 |
| Start date | Jun 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | May 24, 2007 |
| Last update posted | May 17, 2017 |
| Countries | Bulgaria, France, India, Russia, Ukraine, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: